ZYME
Zymeworks Inc

2,597
Mkt Cap
$1.76B
Volume
69,916.00
52W High
$28.49
52W Low
$9.03
PE Ratio
-27.50
ZYME Fundamentals
Price
$23.29
Prev Close
$23.81
Open
$23.30
50D MA
$24.10
Beta
0.91
Avg. Volume
970,910.05
EPS (Annual)
-$1.62
P/B
5.51
Rev/Employee
$266,797.20
$903.13
Loading...
Loading...
News
all
press releases
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of -58.64% and -88.23%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3h ago
News Placeholder
More News
News Placeholder
Zymeworks (NASDAQ:ZYME) Releases Earnings Results, Misses Estimates By $0.20 EPS
Zymeworks (NASDAQ:ZYME - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20...
MarketBeat·3h ago
News Placeholder
Zymeworks Inc. Q4 Loss Widens
(RTTNews) - Zymeworks Inc. (ZYME) announced Loss for its fourth quarter of -$41.209 million...
Nasdaq News: Markets·4h ago
News Placeholder
Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma
(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of...
Nasdaq News: Markets·4h ago
News Placeholder
Earnings Breakdown: Zymeworks Q4
read more...
Benzinga·4h ago
News Placeholder
A Look Ahead: Zymeworks's Earnings Forecast
read more...
Benzinga·3d ago
News Placeholder
Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +7.80% and +1.21%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Key PointsRedmile Group sold 3,214,096 ZYME shares, estimated at $70.10 million based on quarterly average prices...
Nasdaq News: Markets·8d ago
News Placeholder
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) have been given an average recommendation of "Buy" by the seven research firms that are currently covering the company, Marketbeat reports...
MarketBeat·23d ago
News Placeholder
Tejara Capital Ltd Has $1.46 Million Stock Holdings in Zymeworks Inc. $ZYME
Tejara Capital Ltd trimmed its position in Zymeworks Inc. (NYSE:ZYME - Free Report) by 57.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission...
MarketBeat·29d ago
<
1
2
...
>

Latest ZYME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.